Sorry, even NWBO knows their manipulated trial is a 'hail Mary" as they failed to meet the original primary endpoint. They have nothing to lose by totally redoing the protocol, endpoints, comparator and SAP. Confounded data, FDA partially stopped trial, post hoc data dredged endpoint. Anything to present a positive outcome. And NWBO knows it: "There can be no assurance that regulatory authorities will allow a product approval to be based upon this approach."
Investment community didn't buy it -- no positive effect on the share price, down ~50% in the last year AFTER the TLD. If it was truly positive outcome, share price would be up significantly, instead nada.
Market Data 
Markets 
AI
